BOSTON, May 22, 2012 /PRNewswire/ -- Rhythm announced today the results of a Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis.

MILWAUKEE, June 23, 2011 /PRNewswire/ -- A bill to expand federal research of functional gastrointestinal (GI) and motility disorders, such as IBS, GERD and gastroparesis, has been introduced in the U.S. House of Representatives.

BOSTON, May 9, 2011 /PRNewswire/ -- Rhythm announced today results demonstrating that RM-131, the company's novel ghrelin agonist, was highly effective in restoring normal gastric function in animal models of delayed gastric emptying owing to a direct prokinetic effect.

People with severe stomach disorders can sometimes suffer from chronic vomiting.

Diabetes mellitus is one of the most common chronic disease of the world and the prevalence of diabetes mellitus is over 10% in Taiwan.